Invivyd, Inc. announced the pricing of an underwritten public offering of 74,811,404 shares of its common stock at $0.52 per share, raising approximately $50.0 million. Cantor is the sole book-running manager for the offering. The company plans to use the proceeds for trial protocol development, research and development, and general corporate purposes. The offering is expected to close on August 22, 2025, subject to customary closing conditions. Invivyd is a biopharmaceutical company focused on developing protection against serious viral infectious diseases.

This press release contains forward-looking statements regarding the offering’s proceeds and closing timing. Factors such as regulatory approvals, market volatility, and economic conditions may impact actual results. Investors are advised to review risk factors in the preliminary prospectus supplement and other SEC filings. Invivyd does not intend to update forward-looking statements unless required by law. Media and investor relations contacts are available for more information.

Read more at GlobeNewswire: Invivyd Announces Pricing of $50 Million Public Offering of